Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents in Resectable Early-stage NSCLC
2018-002932-26Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab, oleclumab, monalizumab and danvatirsen in non-small cell lung cancer (NSCLC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Clinical activity. Started Feb 2019; status: completed.
02
Drugs
durvalumaboleclumabmonalizumabdanvatirsen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002932-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002932-26.